PBH — Prestige Consumer Healthcare Inc. stock price, charts and financials

QT39Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc. (NYSE: PBH) is a Healthcare company in the Medical - Pharmaceuticals industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
44.97
-1.50-3.23%
PBHQT39Prestige Consumer Healthcare Inc.·NYSE
44.97-3.23%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E12.60EPS (ttm)3.57Insider Own2.09%Shs Outstand47.37MPerf Week-4.22%
Market Cap2.13BForward P/E8.76EPS next Y5.13Insider Trans-0.22%Shs Float46.70MPerf Month-12.98%
Enterprise Value4.09BPEG1.91EPS next Q1.06Inst Own-Short Float9.82%Perf Quarter-4.26%
Income172.00MP/S1.93EPS this Y28.41%Inst Trans-Short Ratio7.79Perf Half Y-25.12%
Sales1.10BP/B1.11EPS next Y11.97%ROA3.77%Short Interest4.58MPerf YTD-27.10%
Book/sh40.47P/C23.94EPS next 5Y6.60%ROE9.22%52W High71.07 -36.72%Perf Year-29.54%
Cash/sh1.88P/FCF9.45EPS past 3/5Y- 3.77%ROIC4.80%52W Low42.62 5.51%Perf 3Y-23.42%
Dividend Est.-EV/EBITDA13.08Sales past 3/5Y-1.17% 2.92%Gross Margin53.26%Volatility3.16% 2.87%Perf 5Y-15.94%
Dividend TTM-EV/Sales3.71EPS Y/Y TTM-16.78%Oper. Margin26.26%ATR (14)1.64Perf 10Y-6.41%
Dividend Ex-DateSep 27, 2018Quick Ratio1.99Sales Y/Y TTM-2.90%Profit Margin15.57%RSI (14)29.94Recom2.47
Dividend Gr. 3/5Y- 8.73%Current Ratio3.23EPS Q/Q-25.76%SMA20-9.89%Beta0.34Target Price81.67
Payout0.00%Debt/Eq0.55Sales Q/Q6.40%SMA50-10.91%Rel Volume3.36Prev Close46.47
Employees890LT Debt/Eq0.55EarningsNov 05SMA200-20.08%Avg Volume572.31KPrice44.97
IPO DateFeb 10, 2005Option/ShortYes / YesEPS/Sales Surpr.9.64% 5.01%Net Debt/EBITDA6.31Volume1,922,828Change-3.23%
Analyst Ratings
DateActionAnalystRatingTarget
May-14-26DowngradeOppenheimerOutperformPerform
Oct-27-25ReiteratedJefferiesHold$71
Nov-05-24ReiteratedCanaccord GenuityBuy$71$86
Jun-21-24UpgradeDA DavidsonNeutralBuy$93
Nov-17-22ReiteratedCanaccord GenuityBuy$71
May-10-22UpgradeJefferiesHoldBuy
May-09-22UpgradeOppenheimerPerformOutperform
Aug-07-20DowngradeDA DavidsonBuyNeutral
Mar-26-20UpgradeJefferiesHoldBuy
Mar-19-20UpgradeDA DavidsonNeutralBuy
Latest News· Times ET
Sep-14-26
Sep-10-26
Sep-08-26
Sep-02-26
Sep-01-26
Aug-28-26
Aug-21-26
Aug-18-26
Aug-16-26
Aug-12-26
Aug-09-26
Aug-09-2605:04PM
Aug-08-26
Aug-06-26
Company

Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2026
3/31/2026
FY 2025
3/31/2025
FY 2024
3/31/2024
FY 2023
3/31/2023
FY 2022
3/31/2022
FY 2021
3/31/2021
FY 2020
3/31/2020
FY 2019
3/31/2019
Total Revenue1,1051,0891,138
Cost of Goods Sold Incl. D&A517514503
Gross Profit588575634
Selling, General and Administrative Excl. Other280265264
Research and Development
000
Other Operating Expense18034
Operating Income290309337
Interest Expense464248
Unusual Expense
Non-Operating Income (Expense)-10-10-5
Net Income Before Taxes235257284
Income Taxes626770
Consolidated Net Income172190215
Net Income From Continuing Operations172190215
Net Income172190215
EPS (Recurring)3.593.934.32
EPS (Basic, Before Extraordinaries)3.593.934.32
EPS (Diluted)3.573.914.29
EBITDA313331362
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio12.6015.1620.04
Price To Sales Ratio1.912.613.78
Gross Margin53.2152.8055.71
Operating Margin26.2428.3729.61
Net Margin15.5717.4518.89
Shares Outstanding474850
Market Capitalization2,1142,8454,299
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$81.67$71.30$60.92$50.55$40.18 Close Price0.00K55.30K110.59K165.89K221.19KUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Zerillo JeffreySenior VP OperationsMay 11 '26Sale52.2835118,35041,810May 12
Zerillo JeffreySenior VP OperationsMay 07 '26Sale54.3630516,58042,161May 11
Zerillo JeffreySenior VP OperationsMay 05 '26Sale55.061,55385,51442,820May 07
Zerillo JeffreySenior VP OperationsFeb 11 '26Sale65.931,00065,93041,048Feb 13
Zerillo JeffreySenior VP OperationsDec 01 '25Sale60.0028116,86042,048Dec 02
Zerillo JeffreySenior VP OperationsNov 28 '25Sale60.0071943,14042,329Dec 02
BYOM JOHN EDirectorNov 25 '25Sale59.353,000178,05051,594Nov 26
Fritz Mary BethSVP Quality & RegulatoryMar 10 '25Sale90.001,678151,02017,157Mar 12
Fritz Mary BethSVP Quality & RegulatoryMar 03 '25Option Exercise44.336,297279,14625,132Mar 05
Fritz Mary BethSVP Quality & RegulatoryMar 03 '25Sale85.396,297537,70118,835Mar 05
Mekhail AdelEVP, Marketing & SalesFeb 11 '25Option Exercise49.5311,083548,93524,048Feb 13
Mekhail AdelEVP, Marketing & SalesFeb 11 '25Sale86.5511,083959,27118,365Feb 13
Lombardi Ronald M.Chief Executive OfficerNov 19 '24Option Exercise56.6210,875615,774326,614Nov 21
Lombardi Ronald M.Chief Executive OfficerNov 19 '24Sale82.6010,875898,241320,952Nov 21
Lombardi Ronald M.Chief Executive OfficerNov 18 '24Option Exercise56.7482,2374,666,226369,464Nov 19
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.